HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Talia B. Spanier Mehmet C. Oz Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, M. R. Articles by Oz, M. C. Search for Related Content PubMed PubMed Citation Articles by Williams, M. R. Articles by Oz, M. C.

Ann Thorac Surg 2000;70:873-877
© 2000 The Society of Thoracic Surgeons

---

Original articles: cardiovascular

A randomized trial of antithrombin concentrate for treatment of heparin resistance

^a Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, New York, USA

Address reprint requests to Dr Williams, Division of Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, 17–401, 630 W 168th St, New York, NY 10032
e-mail: mw365{at}columbia.edu

Background. Heparin resistance is an important clinical problem traditionally treated with additional heparin or fresh frozen plasma. We undertook a randomized clinical trial to determine if treatment with antithrombin (AT) concentrate is effective for treating this condition.

Methods. Patients requiring cardiopulmonary bypass who were considered to be heparin resistant (activated clotting time < 480 seconds after > 450 IU/kg heparin) were randomized to receive either 1000 U AT or additional heparin.

Results. AT concentrate was effective in 42 of 44 patients (96%) for immediately obtaining a therapeutic activated clotting time. This compared favorably to 28 of 41 patients (68%) treated with additional heparin (p = 0.001). All patients who failed heparin therapy were successfully treated with AT. The patients receiving AT required less time to obtain an adequate ACT but there was no difference in clinical outcomes among the groups. Study patients had deficient AT activity at baseline (56% ± 25%), which improved in those given AT concentrate (75% ± 31% versus 50% ± 23%, p < 0.0005).

Conclusions. Heparin resistance is frequently associated with AT deficiency. Treating this deficiency with AT concentrate is more effective and faster for obtaining adequate anticoagulation than using additional heparin.

This article has been cited by other articles:

				B. D. Spiess Treating heparin resistance with antithrombin or fresh frozen plasma. Ann. Thorac. Surg., June 1, 2008; 85(6): 2153 - 2160. [Abstract] [Full Text] [PDF]

				S. Bar-Yosef, H. B. Cozart, B. Phillips-Bute, J. P. Mathew, and H. P. Grocott Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery: [L'heparine de bas poids moleculaire en preoperatoire reduit la reponse a l'heparine pendant la chirurgie cardiaque] Can J Anesth, February 1, 2007; 54(2): 107 - 113. [Abstract] [Full Text] [PDF]

				A. Vincentelli, B. Jude, and S. Belisle Antithrombotic therapy in cardiac surgery: [Traitement antithrombotique en chirurgie cardiaque]. Can J Anesth, June 1, 2006; 53(6_suppl): S89 - S102. [Abstract] [Full Text] [PDF]

				A. K. Wittkowsky Anticoagulation in Hypercoagulable Conditions: Special Considerations in the Treatment and Prevention of Venous Thromboembolism Journal of Pharmacy Practice, October 1, 2004; 17(5): 308 - 316. [Abstract] [PDF]

				J. H. Lemmer Jr and G. J. Despotis Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., February 1, 2002; 123(2): 213 - 217. [Abstract] [Full Text] [PDF]